Insider Selling: Moderna, Inc. (NASDAQ:MRNA) President Sells $12,451.89 in Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 291 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $12,451.89. Following the completion of the sale, the president now owns 1,443,567 shares of the company’s stock, valued at $61,770,231.93. This trade represents a 0.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stephen Hoge also recently made the following trade(s):

• On Tuesday, December 3rd, Stephen Hoge sold 314 shares of Moderna stock. The stock was sold at an average price of $43.30, for a total value of $13,596.20.
• On Tuesday, September 3rd, Stephen Hoge sold 318 shares of Moderna stock. The stock was sold at an average price of $76.99, for a total value of $24,482.82.

Moderna Stock Performance

MRNA stock opened at $41.63 on Thursday. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47. The business’s fifty day moving average price is $51.11 and its 200 day moving average price is $89.24.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.39) EPS. On average, equities research analysts expect that Moderna, Inc. will post -9.32 EPS for the current year.

Institutional Investors Weigh In On Moderna

Large investors have recently bought and sold shares of the stock. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna during the 2nd quarter worth about $26,000. Family Firm Inc. purchased a new stake in Moderna during the 2nd quarter worth about $33,000. Bank & Trust Co purchased a new stake in Moderna during the 2nd quarter worth about $36,000. Hanseatic Management Services Inc. purchased a new stake in Moderna during the 2nd quarter worth about $48,000. Finally, Plato Investment Management Ltd increased its holdings in Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after purchasing an additional 288 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research analyst reports. UBS Group lowered their price target on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. Leerink Partners lowered their price objective on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. JPMorgan Chase & Co. lowered their price objective on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 26th. Finally, Barclays lowered their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and an average price target of $83.33.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.